1346818-11-8

Basic information

• Product Name: 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine
• Synonyms: 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine
• CAS NO: 1346818-11-8
• Molecular Weight: 345.599
• Mol File: 1346818-11-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine(1346818-11-8)
• EPA Substance Registry System: 3-[1-(2-chloro-5-fluorophenyl)ethoxy]-5-bromo-2-aminopyridine(1346818-11-8)

Safety Data

• Hazardous Substances Data: 1346818-11-8(Hazardous Substances Data)

Upstream product

• 700-31-2 (RS)-1-(2-chloro-5-fluorophenyl)ethanol 
• 2965-16-4 1-(2-chloro-5-fluorophenyl)ethan-1-one 
• 74115-13-2 5-bromopyridine-3-ol 
• 691872-15-8 5-bromo-3-hydroxy-2-nitropyridine 

Relevant articles and documents

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors

Janus kinases (JAKs) including JAK1, JAK2, JAK3, and TYK2 are members of a family of intracellular nonreceptor tyrosine kinases, which have been demonstrated to be critical in the cell signaling pathway and involved in inflammatory diseases and cancer. V617F mutation in JAK2 has been implicated in polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF). Here, we described the design, synthesis, and biological evaluation of a series of 2-aminopyridine derivatives. The results of enzymatic activity assays supported compound 16m-(R) as a potential and selective JAK2 inhibitor, which exhibited high inhibitory activity with an IC50 of 3 nM against JAK2, and 85- and 76-fold selectivity over JAK1 and JAK3, respectively. Structure-activity relationships (SAR) and mechanistic analysis demonstrated that 16m-(R) might be a promising selective JAK2 inhibitor for further study.

SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF

Provided is a selective JAK2 inhibitor and application thereof. In particular, it relates to the compound of the following Formula (I), and the use of the compound in the treatment of JAK2-mediated related diseases and in the preparation of the medicament for treating JAK2-mediated related diseases.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.